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Purpose: Vascular endothelial growth factor (VEGF) levels
in malignant ascites have high diagnostic value for their
discrimination from asictes of non-malignant origin. However,
there have been no reports on the comparison of VEGF levels
between malignant ascites of chemonaive and chemotreated
patients. Materials and Methods: VEGF levels were measured
in 44 ascites patients (cirrhosis ascites, 10; chemonaive
patients, 21; chemotreated patients, 13) and compared to the
level of carcinoembryonic antigen (CEA) and carbohydrate
antigen 19 - 9 (CA 19 - 9). The diagnostic parameters of
sensitivity, specificity, and correlation among 3 markers were
evaluated. Results: VEGF levels in malignant ascites of
chemonaive and chemotreated patients were significantly
higher than those in cirrhotic ascites (p < 0.05). VEGF levels
in ascites of chemonaive patients were significantly higher
than those in chemotreated patients (p < 0.05). A cutoff value
of 10.4 pg/mL was calculated using receiver operating charac-
teristic curves (ROCs) for VEGF in chemotreated and
chemonaive patients, which gave sensitivities of 75.0% and
53.8% and specificities of 69.6% and 47.1%, respectively.
Positive correlations were observed between VEGF and CEA
(r = 0.353, p < 0.05) as well as between VEGF and CA19 - 9
(r= 0.367, p < 0.05) in ascites. Conclusion: VEGF levels could
be a useful tumor marker for malignant ascites, but its value
should carefully be interpreted because of lesser reliability in
chemotreated ones.
Key Words: Vascular endothelial growth factor, chemotherapy,
malignant ascites, carbohydrate antigen 19-9, carcinoembryonic
antigen
INTRODUCTION
The differential diagnosis of ascites is important
for detection of underlying disease and treatment
in clinical practice. Lymphatic obstruction and
other factors, including vascular permeability factors
and metalloproteinase, have been considered as
major pathophysiological mechanism of ascites
formation.
1 However, the precise mechanism of its
development is unknown. The detection of
malignant cells in asctic fluid has been the gold
standard for the diagnosis of malignant ascites,
but it has a sensitivity of only 40 - 60%.
2 Other
parameters, such as lactic acid dehydrogenase,
3
C-reactive protein,
4 fibronectin,
5 and cholesterol,
6
have also been studied, nevertheless, none of them
proved to be a fully satisfactory discriminant
between malignant and non-malignant ascites.
VEGF is a unique angiogenic dimeric glyco-
protein with a molecular mass of 34 to 42 kDa,
and it has potent endothelial cell mitotic activity
and vascular permeability activity.
7 VEGF is
involved in the formation of ascites, but its value
in the diagnosis of malignant ascites has not been
fully elucidated.
8,9 It has been reported that VEGF
levels are significantly high in malignant ascites
and serum from patients with ovarian or gastro-
intestinal carcinoma, especially with metastatic
disease.
8,10-12 On the other hand, several chemo-
therapeutic agents appear to inhibit VEGF- induced
angiogenesis in several animal studies.
13-16 The
purpose of this study was to evaluate differences
in VEGF levels in malignant ascites between no
chemotreated (chemonaive) patients and chemo-
received patients due to various malignancies.
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CEA and CA19 - 9 are the most widely used
tumor markers for various cancers, especially
gastrointestinal cancers.
17-19 Tumor markers such
as CEA and CA19 - 9 could also be useful tools in
the differential diagnosis of benign and malignant
effusions.
20 It has been demonstrated that CEA
and CA19 - 9 showed significant sensitivity
difference between patients with malignant-
related ascites and those without malignant-
related ascites.
21,22 Therefore, we measured CEA
and CA19 - 9 to assess the utility of discriminating
malignant from nonmalignant ascites. Furthermore,
we compared VEGF in ascites of chemonaive and
chemotreated patients with conventional tumor
markers such as CEA and CA19 - 9.
MATERIALS AND METHODS
Subjects
Forty-four patients (aged 10 - 90 yr; 26 males
and 18 females), who presented with clinically
detectable ascites, were studied at Uijeongbu St.
Mary’s Hospital of Catholic University of Korea
from March 2005 to April 2006. Patients with
malignant ascites who had not undergone systemic
chemotherapy (n = 21) were defined as group 1,
patients with malignant ascites who had undergone
chemotherapy as group 2 (n = 13, Table 1), and
patients with cirrhotic ascites as group 3 (n = 10,
Table 2), which were transudate ascites of viral
origin (6 cases) and alcoholic origin (4 cases). The
diagnosis of malignant tumors in all patients was
established by primary cancer biopsy (n = 29) and
cytology of ascites (n = 4). Klastkin tumor (group
1, case 10) was diagnosed by CT scan (Table 1).
Liver carcinomas of 2 patients were not accom-
panied by liver cirrhosis. Ascites samples were
collected from the supernatants of all subjects
after centrifugation (900 × g) and stored at - 80
until use. The study protocol was approved by the
ethics committee of Uijeongbu St. Mary's Hospital.
Informed consent was obtained from all patients.
Methods
The ascitic fluid of each patient was analyzed
for VEGF, CEA, CA19 - 9, protein concentration,
and leukocytes counts. In cirrhotic ascites (group
3), leukocyte counts were performed to exclude
bacterial peritonitis as a complication of cirrhosis.
The samples were analyzed in a laboratory of the
Department of Laboratory Medicine, Uijeongbu
St. Mary's Hospital. The concentrations of VEGF
in the ascites were measured using an enzyme-
linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN, USA) according to the
manufacturer's guidelines. The samples were
analyzed in duplicate; human recombinant VEGF
165 was serially diluted and used as the standard.
VEGF concentrations were measured according to
a standard curve. Levels of CEA and CA19 - 9
concentrations were measured in all patients by
radioimmune assay.
23 Previously published cutoff
values for ascitic CEA24 and CA19 - 925 were
used in this study (normal value; CEA < 5 ng/mL,
CA19 - 9 < 37 U/mL). The nature of the ascites
(transudate or exudate) was classified by the use
of Light’s criteria to give a diagnostic sensitivity
of 98% and specificity of 98% for an exudate.26
Ascites showing an ascites/serum protein ratio
greater than 50% were regarded as exudate. The
results of chemotherapy in group 2 were evaluated
as follows: complete response, partial response,
progressive disease, and stable disease. The
response criteria were defined according to WHO
guidelines.
27,28
Statistical analysis
Differences between the groups were examined
using Mann-Whitney test. Differences between
patients with adenocarcinoma and those with
nonadenocarcinoma in group 1 and group 2 were
examined using Mann-Whitney test. The data are
presented as means ± standard deviations. The
relationships between VEGF and the conventional
parameters, CEA and CA19-9, were analyzed
using Spearman's correlation analysis. Data were
analyzed using SPSS software (version 10.0,
Chicago, IL, USA). Differences were considered
significant at p values less than 0.05.
RESULTS
VEGF levels in the malignant ascites of eitherTable 1. Clinical and Pathological Characteristics of Malignant Ascites Patients
Case
No.
Diagnosis and methods
(cancer biopsy/ascites cytology/
other method (CT or US)
Stage Other therapy
(OP or RT)
Ascites/serum
protein ratio (%) CTx
Chemo-
naive
patients
(group 1)
1 Stomach, adeno Ca. (+/+/+) IV None 71 -
2 Stomach, adeno Ca. (+/+/+) IV None ND -
3 MUO, PD Ca. (+/+/+) IV None 63 -
4 Stomach, adeno Ca. (+/+/+) IV None 75 -
5 Stomach, adeno Ca. (+/+/+) IV None 74 -
6 MUO (+/+/+) IV None ND -
7 Colon, adeno Ca. (-/+/+) IV None 88 -
8 GB adeno Ca. (+/+/+) IV None 4 -
9 Stomach, adeno Ca. (+/+/+) IV None 74 -
10 Klastkin tumor (-/-/+) IV None 19 -
11 Stomach, adeno Ca. (+/+/+) IV None 63 -
12 Pancreas adeno Ca. (+/+/+) IV None 72 -
13 HCC, Trabecular type (+/+/+) IV None 14 -
14 MUO, adeno Ca. (-/+/+) IV None 68 -
15 Ovary, adeno Ca. (-/+/+) IV Op 72 -
16 MUO, nonadeno Ca. (-/+/+) IV None 71 -
17 Colon adeno Ca. (+/+/+) IV None 33 -
18 Esophagus, adeno Ca. (+/+/+) IV None 79 -
19 MUO, *PD Ca. (+/+/+) IV None 63 -
20 Colon, adeno Ca. (+/+/+) IV None 73 -
21 Ovary Ca. (+/+/+) IV Op 78 -
Chemo-
treated
patients
(group2)
22 Stomach, adeno Ca. (+/+/+) IV None 15 Docetaxel, 5-fluorouracil x 1
23 Ovary, adeno Ca. (+/+/+) IV Op 80 Carboplatin, paclitaxel x 5
24 Stomach, adeno Ca. (+/+/+) IV None 100 5-Fluorouracil, cisplatin x 6
25 Ovary, adeno Ca. (+/+/+) IV Op 95 Cis-paclitaxel x 8, gelotecan
(topoisomerase inhibitor) x 2
26 Stomach, adeno Ca. (+/+/+) IV None 100 5-Fluorouracil, cisplatin x 6
27 Stomach, adeno Ca. (+/+/+) IV None 91 Paclitaxel/cisplatin x 3, cisplatin,
capecitabine x 2, cisplatin,
docetaxel x 2
28 Stomach, adeno Ca. (+/+/+) IV None 100 Paclitaxel/cisplatin x 6, FOLFIRI
(irinotecan/leucovorin/5-FU) x
3, 5-FU/methotrexate x 1
29 HCC, trabecular type (+/+/+) IV None 42 Epirubicin, cisplatin,
5-fluorouracil
30 Pancreas adeno Ca. (+/+/+) IV None 36 Gemcitabine, 5-fluorouracil,
capecitabine x 2
31 Stomach adeno Ca. (+/+/+) IV None 21 Capecitabine, docetaxel x 6,
irinotecan, cisplatin x 5
32 Rectal adeno Ca. (+/+/+) IV None 56 Folfiri (iritecan, 5-FU,
leukovorin) x 3, oxaliplatin,
xeloda x 1, 5-FU, cisplatin x 2,
FAM (5-FU, adriamycin,
mitomycin) x 1
33 Ovary adeno Ca. (+/+/+) IV Op ND Cytoxan-carboplatin x 2,
docetaxel x cisplatin x 1
34 Bladder Ca., transitional cell type
(+/+/+)
IV None 33 BCG (bacillus calmette guerin) x
6
PD Ca., poorly differentiated carcinoma; Adeno Ca., adenocarcinoma; CT, computed tomography; US, ultrasonography; MUO,
metastasis of unknown origin; OP, operation; RT, radiation therapy; ND, not done; CTx, chemotherapy; P, progression; PR, partial
response; FU, fluorouracil.
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chemonaive patients (349.13 ± 490.76 pg/mL) and
chemotreated patients (51.68 ± 89.26 pg/mL) were
significantly higher than those of patients with
cirrhotic ascites (0.26 ± 0.82 pg/mL) (p < 0.05).
VEGF levels in malignant ascites of the untreated
group were also significantly higher than in the
chemotreated malignant group (p < 0.05). When
patients were evaluated according to pathological
type, VEGF levels in ascites did not differ between
those with adenocarcinoma (n = 17 in group 1, n
= 11 in group 2) and those with nonadenocar-
cinomas (n = 4 in group 1, n = 2 in group 2; p >
0.05).
A cutoff value of 10.4 pg/mL was selected
using ROC curves for VEGF in malignant ascites
of patients in group 1 and group 2, which gave
sensitivities of 75.0% and 53.8%, respectively, and
specificities of 69.6% and 47.1%, respectively (Figs.
1A and B). When cutoff values for CEA and CA19
- 9 were applied, the results obtained were
Table 2. Clinical and Pathological Characteristics in Cirrhotic Patients (Group 3)
Case No. Diagnosis
Ascites/serum protein
ratio (%)
Albumin in serum
(g/dL)
Leukocytes count in ascites
(mm
3)
1 LC (HBV) 19 2.6 10
2 LC (alcoholic) 17 2.7 77
3 LC (HBV) 20 2.6 58
4 LC (alcoholic) 12 2.5 9
5 LC (HBV) 17 2.3 55
6 LC (HBV) 32 2.5 21
7 LC (HBV) 22 2.8 59
8 LC (HBV) 19 1.5 32
9 LC (alcoholic) 31 2.4 30
10 LC (alcoholic) 29 2.5 6
LC, liver cirrhosis; HBV, hepatitis B virus.
Fig. 1. (A) Malignant ascites of chemonaive patients. The areas under the ROC curve were 0.766 (p = 0.002). (B) Malignant
ascites of chemotreated patients. The areas under the ROC curve were 0.462 (p = 0.686). ROC, receiver operating
characteristic. 
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classified into true positive, false positive, true
negative and false negative. Sensitivity and
specificity were then calculated for each
parameter, and the results are shown in Table 3.
Significant correlations were observed between
VEGF levels and ascitic CA19 - 9 in malignant
ascites (r = 0.367, p < 0.05, Fig. 2A). There was also
a significant correlation between VEGF levels and
CEA concentrations in malignant ascites (r = 0.353,
p < 0.05, Fig. 2B).
Forty-one samples (chemonaive 19/21, chemo-
treated 12/13, and cirrhotic ascites 10/10) out of
44 patients were evaluated for exudative or
transudative ascites (Table 1). The fraction of
exudative ascites was 78.9% (15/19) in group 1,
58.3% (7/12) in group 2, and 0% in group 3,
according to Light's criteria. In 3 patients, ascites
measurements were not done. When applying
Light's criteria to all patients, 71.0% and 100% of
sensitivity and specificity, respectively, were
found.
DISCUSSION
Malignant ascites are frequently found during
the progression of cancer and incur significant
morbidity. It has been suggested that VEGF is
involved in the formation of ascites,
9 but its role
as a marker for malignant ascites has not yet been
fully established. A similar observation earlier
described that VEGF plays a role in the formation
of malignant ascites by increasing vascular
permeability.
7,8 This finding suggests that VEGF
might be a useful marker of malignant ascites,
distinguishing it from benign ascites. In the current
Table 3. Diagnostic Value of Individual Parameters in Differentiating Malignant from Nonmalignant Ascites
Parameters Cutoff Sensitivity (%) Specificity (%)
VEGF (Group 1) > 10.4 pg/mL 75.0 69.6
VEGF (Group 2) > 10.4 pg/mL 53.8 47.1
CEA > 5 ng/mL 41.7 80.0
CA19 - 9 > 34 U/mL 58.3 60.0
VEGF, vascular endothelial growth factor; Group 1, malignant ascites of chemonaive patients; Group 2, malignant ascites of
chemotreated patients; CEA, carcinoembryonic antigen; CA19 - 9, carbohydrate antigen 19 - 9.
Fig. 2. (A) Correlation between ascitic VEGF concentrations and CA19 - 9 concentrations in malignant ascites. (B)
Correlation between ascitic VEGF concentrations and CEA concentrations in malignant ascites. VEGF, vascular
endothelial growth factor.
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study, VEGF concentrations in the malignant
ascites of the chemonaive group or chemotreated
group were significantly higher than those of
patients with cirrhotic ascites as a control. On the
other hand, VEGF had better sensitivity than that
of CA19 - 9 or CEA for discriminating between
malignant and nonmalignant ascites. Furthermore
VEGF in ascites alone is an excellent tumor
marker only in chemonaive patients compared to
2 conventional tumor markers.
Several chemotherapeutic agents inhibit VEGF-
induced angiogenesis. There has been no report of
VEGF secretion in malignant ascites, particularly
in chemotreated patients. In this study, we
demonstrated that VEGF levels in chemotreated
group decreased more than those in the untreated
group. This result reaffirms that chemotherapeutic
agents exert antiangiogenic activity. From a
clinical perspective, our study demonstrated that
the clinical significance of VEGF levels in ascites
of chemotreated patients should be interpreted
with care due to low sensitivity and specificity.
In our study, a cutoff value of 10.4 pg/mL was
selected from the ROC curves for VEGF in groups
1 and 2, and this gave sensitivities of 75.0% and
53.8% and specificities of 69.6% and 47.1%, respec-
tively. Our results were lower than the previously
reported values for sensitivity (91.3%) and
specificity (90.9%) for VEGF levels in ascites.
8 We
do not know the reasons for this, nevertheless,
these results might be due to the proportion of
metastatic carcinoma of unknown origin (MUO).
Furthermore, the standard deviations of VEGF
measurements in this study were very large,
possibly due to significant case differences,
including various kinds of malignancy, and 3
patients in group 1 had extremely high levels of
ascitic VEGF concentrations (1000 pg/mL or
more). Two patients in group 2 had ascitic VEGF
concentrations of 200 pg/mL or more resulting in
a large standard deviation.
In this study, there were no significant dif-
ferences in VEGF levels between patients with
adenocarcinomas and those with nonadenocar-
cinomas. In both chemonaive and chemotreated
patients, the presence of different cell types could
not explain their different VEGF levels. These
results are in concordance with earlier studies that
VEGF values did not differ significantly according
to histologic subtype.
12
In this study, significant correlations were
found between VEGF levels and both CEA and
CA19 - 9 concentrations. Until now, there has been
no study on the correlations between VEGF levels
and both CEA and CA19 - 9 concentrations.
However, similar results were reported about the
role of serum VEGF in gastrointestinal cancer;
serum VEGF levels correlated well with those of
CEA and CA19 - 9, according to the progression of
cancer.
29 In our analysis, sensitivity for evaluation
of exudative ascites was lower than expected
because of applying only protein ratio: Light's
criteria consist of 3 criteria (protein ratio, LDH
ratio, and LDH activity). But Loewenstein et al.
reported that a CEA level (> 10 ng/mL) in ascites
suggests malignancy, even if the fluid is
transudative.
30 In our study, 4 cases of malignant
ascites were correctly classified as transudative
malignancy by measurement of CEA. Thererfore,
it is necessary in the future to elucidate the
correlation between several recent tumor markers
as well as conventional markers. The present data
again confirmed the possible role of VEGF as a
new marker for malignant ascites, however, its
value has to be carefully interpreted in patients
with past history of chemotherapy.
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